Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05438212 · ClinicalTrials.gov registry record · Phase 3

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

A Phase 3 study of Metastatic Malignant Neoplasm in the Brain, sponsored by NRG Oncology.

Active
Registry status
Phase 3
Development phase
237
Enrollment target
20
Study locations

NCT05438212 is a Phase 3 study of Metastatic Malignant Neoplasm in the Brain that is active but no longer recruiting, run by NRG Oncology. The registered enrollment target is 237 participants, above the 83-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (186% higher). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05438212, a Phase 3 study of Metastatic Malignant Neoplasm in the Brain, is active but no longer recruiting, sponsored by NRG Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
237 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation to target tumors and minimizes effect on normal surrounding brain tissue. The combination of surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases. This study investigates whether treating with SRS before surgery may be better than SRS after surgery in reducing the possibility of the tumor coming back, reducing or preventing the cancer from spreading to other areas of the brain and reducing the risk of scarring on the brain from radiation.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • RADIATION Stereotactic Radiosurgery
  • PROCEDURE Brain Surgery

Study Locations (20)

California

  • Kaiser Permanente-Anaheim - Anaheim
  • Sutter Auburn Faith Hospital - Auburn
  • Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
  • Kaiser Permanente-Bellflower - Bellflower
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
  • Kaiser Permanente Los Angeles Medical Center - Los Angeles
  • Memorial Medical Center - Modesto
  • Kaiser Permanente-Ontario - Ontario
  • Saint Joseph Hospital - Orange - Orange
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
  • Stanford Cancer Institute Palo Alto - Palo Alto
  • Sutter Cancer Centers Radiation Oncology Services-Roseville - Roseville
  • Sutter Roseville Medical Center - Roseville
  • Sutter Medical Center Sacramento - Sacramento
  • University of California Davis Comprehensive Cancer Center - Sacramento
  • California Pacific Medical Center-Pacific Campus - San Francisco
  • UCSF Medical Center-Parnassus - San Francisco

Arizona

  • Saint Joseph's Hospital and Medical Center - Phoenix
  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Trial Details

FieldValue
Enrollment Target 237 participants
Start Date 2022-10-24
Est. Completion 2027-03-16
Phase Phase 3

Sponsor

NRG Oncology

64 total trials

What the Registry Record Tells You About NCT05438212

The ClinicalTrials.gov registry entry for NCT05438212 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (186% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT05438212 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05438212 about?

NCT05438212 is a clinical study titled "Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases". This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of r...

What is the current status of trial NCT05438212?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 237 participants. The study started on 2022-10-24. Estimated completion is 2027-03-16.

What conditions does trial NCT05438212 study?

This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain.

What interventions are being tested in trial NCT05438212?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Stereotactic Radiosurgery (RADIATION), Brain Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT05438212?

This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05438212 being conducted?

This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Malignant Neoplasm in the Brain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.